Aldeyra Therapeutics Files 8-K
Ticker: ALDX · Form: 8-K · Filed: Apr 3, 2025 · CIK: 1341235
| Field | Detail |
|---|---|
| Company | Aldeyra Therapeutics, INC. (ALDX) |
| Form Type | 8-K |
| Filed Date | Apr 3, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, corporate-events
TL;DR
Aldeyra Therapeutics filed an 8-K on 4/3/25 covering Reg FD, other events, and financials.
AI Summary
Aldeyra Therapeutics, Inc. filed an 8-K on April 3, 2025, reporting on various events. The filing includes information related to Regulation FD disclosures, other events, and financial statements and exhibits. The company, previously known as Aldexa Therapeutics, Inc. and Neuron Systems Inc., is incorporated in Delaware and headquartered in Lexington, MA.
Why It Matters
This 8-K filing provides updates on regulatory disclosures and other corporate events for Aldeyra Therapeutics, Inc., which could impact investors' understanding of the company's current status.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks.
Key Numbers
- 001-36332 — SEC File Number (Identifies the company's filing with the SEC)
- 20-1968197 — IRS Employer Identification No. (Tax identification number for the company)
Key Players & Entities
- Aldeyra Therapeutics, Inc. (company) — Registrant
- Aldexa Therapeutics, Inc. (company) — Former company name
- Neuron Systems Inc (company) — Former company name
- April 3, 2025 (date) — Date of report
FAQ
What specific events are disclosed under Regulation FD?
The filing indicates a Regulation FD Disclosure, but the specific details of the disclosure are not provided in the provided text.
What are the 'Other Events' reported by Aldeyra Therapeutics?
The filing lists 'Other Events' as an item, but the specific nature of these events is not detailed in the provided text.
What is the significance of the 'Financial Statements and Exhibits' section?
This section indicates that financial statements and exhibits are part of the filing, which are crucial for understanding the company's financial health and operational details.
When did Aldeyra Therapeutics change its name from Aldexa Therapeutics, Inc.?
The company changed its name from Aldexa Therapeutics, Inc. on January 2, 2013.
What is Aldeyra Therapeutics' principal executive office address?
The principal executive offices are located at 131 Hartwell Avenue, Suite 320, Lexington, MA 02421.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 3, 2025 regarding Aldeyra Therapeutics, Inc. (ALDX).